Table 2.

Response to anti-seizure medication trials in the cohort n = 95.

Trial	Response†	No. (%)
Response to first ASM	1A (Seizure free no adverse effects) 1B (Seizure free with adverse effects) IIA (Treatment failure without adverse effects) IIB (Treatment failure with adverse effects)	50 (52.6%) 1 (1.1%) 39 (41.1%) 5 (5.3%)
Response to second ASM	1A (Seizure free no adverse effects) 1B (Seizure free with adverse effects) IIA (Treatment failure without adverse effects) IIB (Treatment failure with adverse effects)	23 (24.2%) 0 19 (20.0%) 1 (1.1%))
Response to 3 or more ASM	1A (Seizure free no adverse effects) 1B (Seizure free with adverse effects) IIA (Treatment failure without adverse effects) IIB (Treatment failure with adverse effects)	10 (10.5%) 0 11 (11.6%) 0

^†Based on the ILAE definition for DRE. ASM, anti-seizure medication; ILAE, the International League Against Epilepsy; DRE, drug-resistant epilepsy.